



**IRENE TENNANT, MSc**  
**DIRECTOR OF CLINICAL DEVELOPMENT**

Irene Tennant has more than 20 years of experience in clinical research & development and operations management for leading pharmaceutical and biotechnology companies. For nearly two decades, she has successfully built and led clinical teams supporting the development of first in class treatments in gene medicine, oncology, and infectious diseases. Irene has proven performance leading global projects for Pfizer Oncology and Novartis AG Pharmaceuticals division in Basel, Switzerland. As early as 2005, Irene has supported the development of cell and gene therapy treatments to address solid tumor cancers and degenerative eye diseases using an adenovirus vector-based therapy. Considered a veteran in the cell and gene therapy industry, Irene's experience in gene therapy also includes other vector platforms such as plasmid and lentiviral vectors. Currently, Irene is the Head of Clinical Development at American Gene Technologies (AGT), an emerging gene and cell therapeutics company in Rockville, MD with a proprietary lentiviral platform capable of broad applications including: orphan indications, infectious disease, immunoncology, and monogenic disorders. Irene expects to take AGT's lead candidate for an HIV Cure into the clinic next year, which will be the first ever approach to cure HIV infected persons of the human immunodeficiency virus.

Irene earned her Bachelor of Science in Biology from Cornell University and her Master of Science in Neurobiology from New York University.

**SOCIAL MEDIA (Links to Profiles)**

Company

- LinkedIn - <https://www.linkedin.com/company/american-gene-technologies-international-inc/>
- Twitter - [@americangene](#)
- Facebook - [@amerigene](#)
- Instagram - [@americangenetechologies](#)

Irene Tennant

- LinkedIn - <https://www.linkedin.com/in/irene-tennant-701086a/>

**COMPANY DESCRIPTION in 155 Words**

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented lead candidate for an HIV Cure into the clinic in 2018, and has pioneered a novel immuno-oncology approach of stimulating gamma-delta ( $\gamma\delta$ ) T cells to attack a variety of cancers. Four key patents in AGT's novel immuno-oncology approach have already been granted, and AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine. AGT has developed a (patent-pending) modified gene that is able to express therapeutic levels of phenylalanine hydroxylase (PAH) which it is deploying, along with other proprietary AGT technologies to pursue the development of a cure for Phenylketonuria (PKU). AGT expects to begin clinical activities for PKU in 2019, and liver cancer (AGT's first immuno-oncology therapy) in 2020.

## **COMPANY DESCRIPTION in 142 Words**

AGT is an advanced gene and cell therapeutics company with proprietary technologies having broad applications including: immuno-oncology, infectious disease, and monogenic disorders. AGT has received four patents for its novel immuno-oncology approach of stimulating gamma-delta ( $\gamma\delta$ ) T cells to attack a variety of epithelial cancers. Pre-clinical animal studies demonstrate high efficacy in primary tumors and an abscopal effect in remote tumors. A proof of concept is expected in liver cancer (HCC) in 2020 with AGT collaborator Dr. Dean Felsher of the Stanford Medical School. AGT will take its HIV cure candidate into the clinic around year's end. This cure has been preliminarily confirmed during pilot runs of HIV patient blood. AGT has also developed a synthetic gene that is capable of expressing therapeutic levels of human phenylalanine hydroxylase (PAH) to cure Phenylketonuria (PKU), which is expected to reach the clinic in 2019.

## **COMPANY DESCRIPTION in 99 Words**

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented lead candidate for HIV Cure into the clinic in 2018, and has also pioneered a novel immuno-oncology approach of stimulating gamma-delta ( $\gamma\delta$ ) T cells to attack a variety of cancers. Four key patents in AGT's novel immuno-oncology approach have already been granted, and AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

## **SHORT WEB DESCRIPTION in 50 words, 270 characters**

American Gene Technologies™ is a gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications. AGT expects its patented lead candidate for an HIV cure to enter the clinic in 2018, and it has developed a patented immuno-oncology approach to attack a variety of epithelial cancers.

## **Contact Us**

9640 Medical Center Dr., Rockville, MD 20850

Phone: (301) 337-2100 - Fax: (301) 337-2101

[info@americangene.com](mailto:info@americangene.com) - [www.americangene.com](http://www.americangene.com)

**LinkedIn**    **Twitter** @americangene    **Facebook** @amerigene